Elevai Labs Inc. highlights results from its licensor?s 2022 preclinical studies evaluating the treatment effect of its recently in-licensed asset, EL-22. EL-22 will primarily be commercialized by Elevai Biosciences Inc. Based on its licensor?s 2022 preclinical data, Elevai believes that EL-22 has the potential to treat obesity in combination with GLP-1 receptor agonists by preserving muscle mass while decreasing fat mass. Specifically, in the preclinical studies: EL-22 showed a statistically significant increase in anti-myostatin IgG antibody concentration, where myostatin is a key negative regulator of muscle growth.

Statistically significant decrease in creatine kinase levels, which indicates a decrease of muscle destruction. EL-22 administered to mdx mice, a mouse model of Duchenne muscular dystrophy, had improved physical activity and gross motor function, as demonstrated by a longer duration during rotarod tests. Based on the highlighted preclinical data, Elevai believes that EL-22 has the potential to treat obesity in combination with GLP-1 by preserving muscle mass while decreasing fat mass.

The Company intends to complete an IND submission in 2025 and to initiate clinical trials in the U.S. to evaluate the myostatin approach in combination with one or more GLP-1 receptor agonists in obesity.